These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30476369)

  • 21. Tardive oculogyric crisis associated with quetiapine use.
    Ghosh S; Dhrubajyoti B; Bhattacharya A; Roy D; Saddichha S
    J Clin Psychopharmacol; 2013 Apr; 33(2):266. PubMed ID: 23422400
    [No Abstract]   [Full Text] [Related]  

  • 22. The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
    Ince E; Algedik P; Demirdogen ES; Emul M; Demir T
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):378-9. PubMed ID: 25920038
    [No Abstract]   [Full Text] [Related]  

  • 23. Tardive oculogyric crisis during treatment with clozapine: report of three cases.
    Uzun O; Doruk A
    Clin Drug Investig; 2007; 27(12):861-4. PubMed ID: 18020545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mild Hypothermia in a Child with Low-Dose Risperidone.
    Grau K; Plener PL; Gahr M; Denzer C; Freudenmann RW
    Z Kinder Jugendpsychiatr Psychother; 2017 Jul; 45(4):335-337. PubMed ID: 27685194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
    Silver H; Aharon N; Schwartz M
    J Clin Psychopharmacol; 2000 Feb; 20(1):112-4. PubMed ID: 10653224
    [No Abstract]   [Full Text] [Related]  

  • 27. Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
    Stämpfli D; Weiler S; Burden AM
    Eur Child Adolesc Psychiatry; 2021 Jul; 30(7):1047-1058. PubMed ID: 32621088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone and withdrawal dyskinesia.
    Lore C
    J Am Acad Child Adolesc Psychiatry; 2000 Aug; 39(8):941. PubMed ID: 10939219
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J; Döpfner M; Lehmkuhl G; ; Uebel H; Schmeck K; Poustka F; Gerber WD; Günter M; Knölker U; Gehrke M; Hässler F; Resch F; Brünger M; Ose C; Fischer R
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
    McLaren JL; Cauble S; Barnett RJ
    J Clin Psychopharmacol; 2010 Feb; 30(1):77-8. PubMed ID: 20075654
    [No Abstract]   [Full Text] [Related]  

  • 33. Epistaxis as an Unexpected Side Effect of Aripiprazole and Risperidone Treatment in Two Children with Two Different Psychiatric Diagnosis.
    Binici NC; Güney SA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):759-760. PubMed ID: 28665688
    [No Abstract]   [Full Text] [Related]  

  • 34. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medication-related oculogyric crises: a description of four cases and a review of the literature].
    Darling A; Poo P; Perez-Duenas B; Campistol J
    Rev Neurol; 2013 Feb; 56(3):152-6. PubMed ID: 23359076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypharmacy and EPS in a child; a case report.
    Tahiroglu AY; Avci A
    Psychopharmacol Bull; 2007; 40(2):129-33. PubMed ID: 17514191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine-induced oculogyric crisis.
    Desarkar P; Das A; Sinha VK
    Aust N Z J Psychiatry; 2006 Apr; 40(4):374. PubMed ID: 16620322
    [No Abstract]   [Full Text] [Related]  

  • 38. [Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
    Rothermel B; Poustka L; Banaschewski T; Becker K
    Z Kinder Jugendpsychiatr Psychother; 2010 Mar; 38(2):123-9; quiz 130. PubMed ID: 20200829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of side effect of antipsychotic on the course of treatment in adolescent.
    Graovac M; Ruzić K; Rebić J; Dadić-Hero E; Francisković T
    Psychiatr Danub; 2010 Mar; 22(1):108-11. PubMed ID: 20305603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program.
    Gardner DM; Abidi S; Ursuliak Z; Morrison J; Teehan MD; Tibbo PG
    J Clin Psychopharmacol; 2015 Dec; 35(6):715-8. PubMed ID: 26485339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.